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A B S T R A C T
We present a case of mild, adult-onset dopa-responsive dystonia (DRD) with a heterozygous mutation in the
tyrosine hydroxylase (TH) gene. We propose that this genetic state may have led to partial enzyme deficiency.
Future studies should attempt to identify and characterize the phenotype of other patients with single TH var-
iants.
1. Manuscript
Dopa-responsive dystonia (DRD) refers to a group of hereditary
dystonias that improve with levodopa. Heterozygous mutations af-
fecting the guanosine triphosphate cyclohydrolase (GCH1) gene cause
the most common and mildest form of DRD, with dystonic features
typically manifesting in childhood. Autosomal recessive GCH1 cases
tend to be more severe [1]. Biallelic mutations in the sepiapterin re-
ductase (SPR), 6-pyruvoyl tetrahydropterin (PTP) synthase and tyrosine
hydroxylase (TH) genes typically lead to more severe phenotypes and
present earlier in life. In TH deficiency, isolated dystonia is uncommon;
patients have parkinsonism and/or a complex disorder combining
dystonia, other movement disorders (tremor, myoclonus, oculogyric
crisis) plus additional features [1]. Patients with TH deficiency have
previously been classified as either type A which manifests in the first
few years of life (range 2 months–5 years) and is characterized by a
progressive hypokinetic-rigid syndrome with dystonia, or type B which
manifests sooner after birth (range 0–3 months) with a more complex
encephalopathy (including the varied movements disorders described
above plus intellectual impairment and autonomic dysfunction) [2].
Here, we report a patient with mild, adult-onset DRD with two het-
erozygous variants on the same allele of the TH gene. Written informed
consent for publication was obtained from the patient.
A 65-year-old man developed left foot dystonia without diurnal
fluctuations aged 38 years. There was no history of other complaints
such as oculogyric crises or autonomic dysfunction. Two years later,
levodopa-carbidopa 100/25mg 1 tablet once daily resulted in a dra-
matic and sustained response, allowing him to continue working as a
post-office courier until his planned retirement. He had no problems
with motor dexterity. He retained mildly abnormal posturing of his
fingers, mild stiffness of his legs (particularly on the left side), neither of
which improved with higher levodopa dosage. On three occasions, le-
vodopa withdrawal resulted in gradual re-emergence of foot dystonia
over months. He never developed dyskinesias or motor fluctuations in
response to levodopa.
He had no children. His deceased father, examined in his 80s, had
some jerky hand movements but no neurological diagnosis was made.
His deceased mother had isolated excessive eye blinking throughout
most of her adult life.
When last examined, he had clawing of the toes, left-sided jerks of
individual fingers, semi-rhythmic movements of the hands when arms
were outstretched (consistent with dystonic tremor), mildly increased
tone in both upper limbs, but no bradykinesia. Gait was normal.
Fluorodopa PET imaging performed aged 41 was normal. The pa-
tient declined CSF neurotransmitter testing. No mutations in GCH1 or
SPR genes were found. The GCHI, TH, and SPR genes were analyzed by
PCR and sequencing of both DNA strands of the entire coding region
and the highly conserved exon-intron splice junctions. Multiplex liga-
tion-dependent probe amplification (MLPA) analyses were performed
for GCHI and TH. TH gene analysis showed a pathogenic variant
(c.296del [p.Leu99Argfs*15]) and a variant of uncertain significance
(c.1169C > T [p.Ser390Leu]), which were confirmed to be present on
the same allele using a comprehensive third-generation sequencing
approach (see Supplemental Methods).
To our knowledge, only biallelic TH-DRD cases have been reported
to date [3]. A 2010 study described 36 TH-DRD cases and reviewed all
previously published cases: the oldest age of onset was 5 years [2].
Since then, others have reported onset at older ages (7, 12 and 18 years)
[3–5]. If the present TH mutation is the cause of our patient's DRD, he
has by far the oldest age of onset and is the only one with a mild
phenotype of isolated dystonia resembling GCH1-DRD.
As in some other recessive disorders, we hypothesize that hetero-
zygosity in TH-DRD could lead to a benign form of a typically severe
disease, possibly due to a mild reduction in TH activity. Supporting this
hypothesis, a small but significant reduction in striatal levodopa was
observed in the post-mortem brain tissue of a heterozygous knock-in
mouse model replicating a human TH mutation, as opposed to the
profound reduction seen in the homozygous mouse model, demon-
strating that the effect may be dependent on gene dosage [6]. Further
studies of adult-onset DRD cases without GCH1 mutations may identify
similar cases and provide further insights into the genetic spectrum of
this condition.
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